United States Pharmaceuticals

Biomarin Pharmaceutical Inc (BMRN)

Track

Biomarin Pharmaceutical Inc. experienced multiple divestments by executives, with the most recent activity occurring on May 7, 2026. These transactions involved planned sales of equity by leadership members. No buying activity was recorded during this period, reflecting a consistent pattern of liquidation among key personnel over the past several months.
Ticker: BMRN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Biomarin Pharmaceutical Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 7 May 2026
Value US$4,041,931.51 | Price 83.38 | Shares 46,993 (+30.9%)
Proposed sale 7 May 2026
Value US$583,950.69 | Price 89.31 | Shares 92,030
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-05-11 2026-05-07 S Sale
2.7
Friberg Gregory R

EVP, Chief R&D Officer

Officer
46,993 +30.9%
83.38
US$4,041,932 		46,993 +30.9% 83.38 US$4,041,932
2026-05-07 2026-05-07 PrS Proposed sale
2.7
Friberg Gregory R

Officer

Officer
92,030
89.31
US$583,951 		92,030 89.31 US$583,951
2026-03-12 2026-03-11 S Sale
3.7
Guyer Charles Greg

EVP, Chief Technical Officer

Officer
36,003 +34.1%
180.00
US$4,954,275 		36,003 +34.1% 180.00 US$4,954,275
2026-03-11 2026-03-11 PrS Proposed sale
3.7
Guyer Charles Greg

Officer

Officer
16,486
60.46
US$996,749 		16,486 60.46 US$996,749
2026-02-26 2026-02-26 S Sale
2.7
Friberg Gregory R

EVP, Chief R&D Officer

Officer
6,326 -14.4%
60.38
US$381,937 		6,326 -14.4% 60.38 US$381,937
2026-02-26 2026-02-26 S Sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
26,061 -26.5%
61.36
US$1,599,103 		26,061 -26.5% 61.36 US$1,599,103
2026-02-26 2026-02-26 PrS Proposed sale
2.7
Friberg Gregory R

Officer

Officer
6,326
60.38
US$381,937 		6,326 60.38 US$381,937
2026-02-26 2026-02-26 PrS Proposed sale
3.1
Davis George Eric

Officer

Officer
26,061
61.36
US$1,599,103 		26,061 61.36 US$1,599,103
2025-05-20 2025-05-20 PrS Proposed sale
Burkhart Erin

Officer

Officer
1,786
59.31
US$105,928 		1,786 59.31 US$105,928
2025-05-20 2025-05-20 PlS Planned sale
Burkhart Erin

GVP, Chief Accounting Officer

Officer
1,786 -11.2%
59.31
US$105,928 		1,786 -11.2% 59.31 US$105,928
2025-05-06 2025-05-02 PlS Planned sale
Hubbard Cristin

EVP, Chief Commercial Officer

Officer
273 -0.8%
64.92
US$17,723 		273 -0.8% 64.92 US$17,723
2025-05-02 2025-05-02 PrS Proposed sale
Hubbard Cristin

Officer

Officer
273
64.92
US$17,723 		273 64.92 US$17,723
2025-03-20 2025-03-19 PlS Planned sale
Burkhart Erin

GVP, Chief Accounting Officer

Officer
1,295 -7.1%
71.52
US$92,618 		1,295 -7.1% 71.52 US$92,618
2025-03-19 2025-03-19 PrS Proposed sale
Burkhart Erin

Officer

Officer
1,295
71.52
US$92,618 		1,295 71.52 US$92,618
2025-03-07 2025-03-06 S Sale
3.7
Guyer Charles Greg

EVP, Chief Technical Officer

Officer
7,034 -7.4%
71.28
US$501,355 		7,034 -7.4% 71.28 US$501,355
2025-03-06 2025-03-06 PrS Proposed sale
3.7
Guyer Charles Greg

Officer

Officer
7,034
71.28
US$501,359 		7,034 71.28 US$501,359
2025-02-25 2025-02-24 PlS Planned sale
Burkhart Erin

GVP, Chief Accounting Officer

Officer
1,344 -9.3%
68.38
US$91,903 		1,344 -9.3% 68.38 US$91,903
2025-02-24 2025-02-24 PrS Proposed sale
Burkhart Erin

Officer

Officer
1,344
68.38
US$91,903 		1,344 68.38 US$91,903
2024-11-14 2024-11-12 S Sale
3.7
Guyer Charles Greg

EVP, Chief Technical Officer

Officer
5,278 -7.1%
66.37
US$350,324 		5,278 -7.1% 66.37 US$350,324
2024-11-12 2024-11-12 PrS Proposed sale
3.7
Guyer Charles Greg

Officer

Officer
5,278
66.37
US$350,324 		5,278 66.37 US$350,324
2024-08-15 2024-08-13 PlS Planned sale
Burkhart Erin

GVP, Chief Accounting Officer

Officer
714 -4.7%
90.00
US$64,260 		714 -4.7% 90.00 US$64,260
2024-08-13 2024-08-13 PrS Proposed sale
Burkhart Erin

Officer

Officer
714
90.00
US$64,260 		714 90.00 US$64,260
2024-06-04 2024-06-04 PrS Proposed sale
3.0
Ajer Jeffrey Robert

Officer

Officer
5,000
76.80
US$384,000 		5,000 76.80 US$384,000
2024-05-31 2024-05-31 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Former Director

Non-Executive Director
31,000
74.54
US$2,310,740 		31,000 74.54 US$2,310,740
2024-05-31 2024-05-30 PlS Planned sale
Mueller Brian

EVP, Chief Financial Officer

Officer
5,000 -6.5%
75.19
US$375,950 		5,000 -6.5% 75.19 US$375,950
2024-05-30 2024-05-30 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Former Director

Non-Executive Director
20,000
75.19
US$1,503,800 		20,000 75.19 US$1,503,800
2024-05-30 2024-05-30 PrS Proposed sale
Mueller Brian

Officer

Officer
5,000
75.19
US$375,950 		5,000 75.19 US$375,950
2024-05-30 2024-05-30 PrS Proposed sale
3.1
LAWLIS V BRYAN

Director

Non-Executive Director
6,600
75.19
US$496,254 		6,600 75.19 US$496,254
2024-05-29 2024-05-29 PrS Proposed sale
3.0
Ajer Jeffrey Robert

Officer

Officer
15,700
73.98
US$1,161,486 		15,700 73.98 US$1,161,486
2024-05-30 2024-05-28 PlS Planned sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
2,779 -4.7%
75.29
US$209,225 		2,779 -4.7% 75.29 US$209,225
2024-05-30 2024-05-28 PlS Planned sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
38,071 -39.2%
74.46
US$2,834,576 		38,071 -39.2% 74.46 US$2,834,576
2024-05-28 2024-05-28 PrS Proposed sale
3.1
Davis George Eric

Officer

Officer
40,850
75.69
US$3,091,936 		40,850 75.69 US$3,091,936
2024-05-13 2024-05-10 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
81.14
US$1,622,800 		20,000 -4.0% 81.14 US$1,622,800
2024-05-13 2024-05-10 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
81.14
US$1,622,800 		20,000 -4.0% 81.14 US$1,622,800
2024-05-10 2024-05-10 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
20,000
81.14
US$1,622,800 		20,000 81.14 US$1,622,800
2024-05-13 2024-05-09 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
81.62
US$1,632,400 		20,000 -4.0% 81.62 US$1,632,400
2024-05-13 2024-05-09 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
81.62
US$1,632,400 		20,000 -4.0% 81.62 US$1,632,400
2024-05-09 2024-05-09 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
20,000
81.62
US$1,632,400 		20,000 81.62 US$1,632,400
2024-05-06 2024-05-02 PlS Planned sale
3.0
Ajer Jeffrey Robert

EVP, Chief Commercial Officer

Officer
5,000 -7.0%
82.91
US$414,550 		5,000 -7.0% 82.91 US$414,550
2024-05-06 2024-05-02 PlS Planned sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
1,850 -3.2%
85.01
US$157,268 		1,850 -3.2% 85.01 US$157,268
2024-05-02 2024-05-02 PrS Proposed sale
3.1
Davis George Eric

Officer

Officer
1,850
85.01
US$157,262 		1,850 85.01 US$157,262
2024-05-02 2024-05-02 PrS Proposed sale
3.0
Ajer Jeffrey Robert

Officer

Officer
5,000
82.91
US$414,550 		5,000 82.91 US$414,550
2024-04-15 2024-04-12 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
91.26
US$1,825,200 		20,000 -4.0% 91.26 US$1,825,200
2024-04-12 2024-04-12 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
20,000
91.26
US$1,825,200 		20,000 91.26 US$1,825,200
2024-04-15 2024-04-11 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
20,000 -4.0%
90.99
US$1,819,800 		20,000 -4.0% 90.99 US$1,819,800
2024-04-11 2024-04-11 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
20,000
90.99
US$1,819,800 		20,000 90.99 US$1,819,800
2024-04-12 2024-04-10 PlS Planned sale
Burkhart Erin

GVP, Chief Accounting Officer

Officer
2,286 -12.4%
90.00
US$205,740 		2,286 -12.4% 90.00 US$205,740
2024-04-10 2024-04-10 PrS Proposed sale
Burkhart Erin

Officer

Officer
2,286
90.00
US$205,740 		2,286 90.00 US$205,740
2024-04-01 2024-03-28 PlS Planned sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
24,602 -30.6%
88.34
US$2,173,341 		24,602 -30.6% 88.34 US$2,173,341
2024-03-28 2024-03-28 PrS Proposed sale
3.1
Davis George Eric

Officer

Officer
24,602
88.34
US$2,173,341 		24,602 88.34 US$2,173,341
2024-03-07 2024-03-06 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -0.2%
86.71
US$86,713 		1,000 -0.2% 86.71 US$86,713
2024-03-06 2024-03-06 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
1,000
86.71
US$86,713 		1,000 86.71 US$86,713
2024-03-07 2024-03-05 PlS Planned sale
3.0
Ajer Jeffrey Robert

EVP, Chief Commercial Officer

Officer
4,000 -4.1%
87.07
US$348,280 		4,000 -4.1% 87.07 US$348,280
2024-03-07 2024-03-05 S Sale
2.5
FUCHS HENRY J

President, Worldwide R&D

Officer
35,341 -14.3%
85.18
US$3,010,396 		35,341 -14.3% 85.18 US$3,010,396
2024-03-07 2024-03-05 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -0.2%
85.51
US$85,510 		1,000 -0.2% 85.51 US$85,510
2024-03-05 2024-03-05 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
1,000
85.51
US$85,510 		1,000 85.51 US$85,510
2024-03-05 2024-03-05 PrS Proposed sale
2.5
FUCHS HENRY J

Officer

Officer
35,341
85.18
US$3,010,397 		35,341 85.18 US$3,010,397
2024-03-05 2024-03-05 PrS Proposed sale
3.0
Ajer Jeffrey Robert

Officer

Officer
4,000
87.07
US$348,280 		4,000 87.07 US$348,280
2024-02-29 2024-02-27 S Sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
1,000 -0.2%
90.35
US$90,350 		1,000 -0.2% 90.35 US$90,350
2024-02-27 2024-02-27 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
1,000
90.35
US$90,350 		1,000 90.35 US$90,350
2024-02-12 2024-02-09 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
15,000 -3.5%
88.28
US$1,324,200 		15,000 -3.5% 88.28 US$1,324,200
2024-02-09 2024-02-09 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
15,000
88.28
US$1,324,200 		15,000 88.28 US$1,324,200
2024-02-12 2024-02-08 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
15,000 -3.5%
89.77
US$1,346,550 		15,000 -3.5% 89.77 US$1,346,550
2024-02-08 2024-02-08 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
15,000
89.77
US$1,346,550 		15,000 89.77 US$1,346,550
2024-01-11 2024-01-10 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -2.3%
96.38
US$963,800 		10,000 -2.3% 96.38 US$963,800
2024-01-10 2024-01-10 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director

Non-Executive Director
10,000
96.38
US$963,800 		10,000 96.38 US$963,800
2024-01-11 2024-01-09 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -2.3%
98.19
US$981,900 		10,000 -2.3% 98.19 US$981,900
2024-01-09 2024-01-09 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director; Former Officer

Executive Director
10,000
98.19
US$981,900 		10,000 98.19 US$981,900
2023-12-22 2023-12-21 PlS Planned sale
2.9
BIENAIME JEAN JACQUES
Non-Executive Director
10,000 -2.3%
93.99
US$939,900 		10,000 -2.3% 93.99 US$939,900
2023-12-21 2023-12-21 PrS Proposed sale
2.9
BIENAIME JEAN JACQUES

Director; Former Officer

Executive Director
10,000
93.99
US$939,900 		10,000 93.99 US$939,900
2023-12-14 2023-12-13 PlS Planned sale
3.1
Davis George Eric

EVP, Chief Legal Officer

Officer
13,764 -19.8%
95.30
US$1,311,709 		13,764 -19.8% 95.30 US$1,311,709
2023-12-13 2023-12-13 PrS Proposed sale
3.1
Davis George Eric

Officer

Officer
13,764
95.30
US$1,311,709 		13,764 95.30 US$1,311,709
2023-08-17 2023-08-16 PlS Planned sale
3.0
Ajer Jeffrey Robert

EVP, Chief Commercial Officer

Officer
5,000 -7.6%
90.00
US$450,000 		5,000 -7.6% 90.00 US$450,000
2023-08-16 2023-08-16 PrS Proposed sale
3.0
Ajer Jeffrey Robert

Officer

Officer
5,000
90.00
US$450,000 		5,000 90.00 US$450,000
2023-08-11 2023-08-10 S Sale
2.5
FUCHS HENRY J

President, Worldwide R&D

Officer
12,000 -6.4%
90.43
US$1,085,111 		12,000 -6.4% 90.43 US$1,085,111
Explore more

More insider trading research around Biomarin Pharmaceutical Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America